Recognizing the breadth of application of its patented extracorporeal treatment approach, Halberd Corporation (OTC-PINK: "HALB”) announced the creation of a subgroup of researchers to focus on cancer treatment. Halberd’s technology is capable of being applied to many diseases, and management decided to not delay the development of potential cancer treatments. The subgroup will be guided ...
Jackson Center, PA, June 8, 2022 – Halberd Corporation (OTC-PINK: "HALB”) and Mississippi State University (MSU) executed a non-disclosure agreement (NDA) to explore animal testing as the next step in obtaining FDA certification for Halberd’s patented extracorporeal disease eradication processes. Consistent with its press release of May 18, 2022, Halberd commenced its pursuits with mdi ...
Jackson Center, PA, May 24, 2022 – Halberd Corporation (OTC-PINK: "HALB”) researchers have demonstrated a protocol which allows for the precise level of elimination of a specific targeted cytokine from a homogeneous mixture of two different cytokines in a fluid. Several adverse health conditions are caused by excess quantities of particular components in blood or ...
Jackson Center, PA, May 18, 2022 – Halberd Corporation (OTC-PINK: "HALB”) has engaged the services of mdi Consultants, Inc. (mdi) to assist Halberd in navigating the U.S. Food and Drug Administration’s (FDA) complex application and certification processes. mdi will guide Halberd on the FDA application and testing protocol and assist in filing the appropriate documents ...
Jackson Center, PA, May 12, 2022 – Halberd Corporation (OTC-PINK: "HALB”) submitted its fully audited financials through its fiscal second quarter and Form-10 to the SEC as its initial step to up-list from OTC-PINK to OTCQB on the OTC Markets exchange. Once Halberd’s shares are qualified under the Securities Exchange Act of 1934 (the “34 ...
Jackson Center, PA, April 27, 2022 – A key member of Halberd Corporation’s (OTC PINK:HALB) Research Team, Dr. W. Gregg Sturrus, recently gave a TEDx Talk® on Halberd’s patented and patent-pending extracorporeal elimination of neurodegenerative disease proteins and cytokines using lasers and metallic nanoparticles. Dr. Sturrus, in his talk, provided a brief ...
Q1 Accomplishments and Q2 Plans Jackson Center, PA, April 25, 2022 Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC: HALB) This past quarter has witnessed some very significant technical and organizational achievements by the Halberd team. Q1 OVERVIEW AND ACHIEVEMENTS Halberd demonstrated elimination of the final two of the “Top Ten” antigens linked ...
Jackson Center, PA, April 11, 2022 – Halberd Corporation (OTC PINK:HALB) announces plans to enter the Metaverse by the creation of nonfungible tokens (NFT’s) to monetize certain intellectual properties of the company including but not limited to patents, patents pending, trade secrets, etc. Halberd is currently in negotiations to engage a team of experts in ...
Jackson Center, PA, April 4, 2022 – Halberd Corporation (OTC PINK:HALB) demonstrated the extracorporeal elimination of C-Reactive Protein from cerebral spinal fluid (CSF) by exposure to tuned laser light, in vitro. Halberd, encouraged by its recent success in eliminating all ten of the top antigens associated with PTSD (Post Traumatic Stress Disorder), CTE (Chronic Traumatic ...
Halberd Corporation Brief Overview Halberd Corporation was re-formed in May 2020. Noting that Halberd’s unique extracorporeal technological approach is adaptable to many disease states, Halberd’s team of professionals employed its skills, resources and focus to concentrate on developing treatments against some of the world’s more persistent diseases, such as, Alzheimer’s Disease, PTSD, ...